What happened
Prestige Biologics updated a previously disclosed supply contract with Celltrion, now worth US$1.36M, about 15.4% of its recent annual revenue, running through Jul 2026.
For context, this single contract equals about 15.4% of the company's most recent annual revenue.
| Counterparty | Celltrion |
|---|---|
| Contract value | US$1.36M |
| vs. recent revenue | 15.4% |
| Through | Jul 2026 (from Dec 2025) |
| Filed | 2026-07-31, [Amended] Supply contract signed |
| Source | DART rcept 20260731900261 → open original filing |
Source: DART. Information only, not investment advice.